As reported above, options for frontline therapy in progressed patients with BRAF-mutated melanoma include checkpoint inhibition and BRAF/MEK inhibition; however, no consensus has been reached on treatment choice and correct sequencing of therapy. This evidence concerns the gene MAP2K7 and melanoma.